Ocugen stock soars after partner Bharat Biotech ** vaccine candidate shows 81% efficacy

小虎综合资讯

Shares of Ocugen Inc. soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its ** vaccine candidate, COVAXIN, which demonstrated efficacy of 81%. Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups. "These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States," said Ocugen Chief Executive Shankar Musunuri. "COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against **." Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

11

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":365775662,"tweetId":"365775662","gmtCreate":1614783209452,"gmtModify":1704775199824,"author":{"id":3527667586584720,"idStr":"3527667586584720","authorId":3527667586584720,"authorIdStr":"3527667586584720","name":"小虎综合资讯","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":4,"userType":4,"introduction":"小虎综合资讯台，一网打尽前沿信息！","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":21187,"starInvestorFlag":false},"themes":[],"images":[{"img":"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8","width":"1068","height":"517"}],"coverImages":[{"img":"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8","width":"1068","height":"517"}],"title":"Ocugen stock soars after partner Bharat Biotech ** vaccine candidate shows 81% efficacy","extraTitle":"","html":"<html><head></head><body><p>Shares of Ocugen Inc. soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its ** vaccine candidate, COVAXIN, which demonstrated efficacy of 81%. Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups. \"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri. \"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against **.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p> <p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\"></p></body></html>","htmlText":"<html><head></head><body><p>Shares of Ocugen Inc. soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its ** vaccine candidate, COVAXIN, which demonstrated efficacy of 81%. Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups. \"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri. \"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against **.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&amp;P 500 has gained 5.6%.</p> <p><img src=\"https://static.tigerbbs.com/89ef5f4dcb688419ea9c6f73c920ffb8\" tg-width=\"1068\" tg-height=\"517\"></p></body></html>","text":"Shares of Ocugen Inc. soared 41.0%, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its ** vaccine candidate, COVAXIN, which demonstrated efficacy of 81%. Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups. \"These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States,\" said Ocugen Chief Executive Shankar Musunuri. \"COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against **.\" Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.","highlighted":1,"essential":1,"paper":2,"likeSize":11,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/365775662","repostId":0,"isVote":1,"tweetType":1,"viewCount":1836,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":939,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/365775662"}